F2 Vision SCS - May 12, 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
10%+ Owner
Signature
F2 Vision SCS /s/ Alain Renard /s/ Christian Francois
Stock symbol
CGEM
Transactions as of
May 12, 2022
Transactions value $
-$4,045,791
Form type
4
Date filed
5/16/2022, 08:54 PM
Previous filing
Jan 13, 2022
Next filing
Aug 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$2.44M -264K -15.31% $9.25 1.46M May 12, 2022 Direct F1, F2
transaction CGEM Common Stock Sale -$850K -85.3K -5.84% $9.96 1.38M May 13, 2022 Direct F2, F3
transaction CGEM Common Stock Sale -$358K -34.2K -2.49% $10.48 1.34M May 13, 2022 Direct F2, F4
transaction CGEM Common Stock Sale -$395K -35.2K -2.62% $11.23 1.31M May 16, 2022 Direct F2, F5
holding CGEM Common Stock 1.14M May 12, 2022 By Globeways Holdings Ltd. F6
holding CGEM Common Stock 639K May 12, 2022 By F2 Bioscience I 2017 Ltd. F7
holding CGEM Common Stock 325K May 12, 2022 By F2 MG Ltd. F8
holding CGEM Common Stock 622K May 12, 2022 By F2-TPO Investments, LLC F9
holding CGEM Common Stock 71.6K May 12, 2022 By F2 Bio TD, LLC F10
holding CGEM Common Stock 215K May 12, 2022 By F2 MC, LLC F11
holding CGEM Common Stock 105K May 12, 2022 By F2 GC, LLC F12
holding CGEM Common Stock 113K May 12, 2022 By Morana Jovan-Embiricos F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.58, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F2 These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $10.395, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 to $10.65, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F7 These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F8 These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F9 These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F10 These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F11 These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F12 These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F13 These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.